13F filer · CIK 1777015
Parkman Healthcare Partners LLC
STAMFORD, CT · filing since Q4 2019 · last filing Aug 14, 2026
Reported value
$976.8M
+$7.2M vs prior
Positions
77
New / sold out
18 / 31
Added / reduced
27 / 30
Turnover
28.3%
buys $275.9M · sells $366.9M
Top-10 weight
33.5%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | INHIBRX BIOSCIENCES INC | +256,950 | – | +$24.3M |
| New | UNITEDHEALTH GROUP INC | +55,921 | – | +$23.2M |
| Added | VIRIDIAN THERAPEUTICS INC | +819,640 | +146.9% | +$15.1M |
| New | INDIVIOR PHARMACEUTICALS INC | +364,269 | – | +$14.9M |
| New | AVALO THERAPEUTICS INC | +766,290 | – | +$14.2M |
| Added | STRUCTURE THERAPEUTICS INC | +253,568 | +109.3% | +$13.6M |
| Added | BRIGHT MINDS BIOSCIENCES INC | +164,955 | +411.4% | +$11.6M |
| New | ALTO NEUROSCIENCE INC | +429,035 | – | +$11.3M |
| New | ORUKA THERAPEUTICS INC | +113,188 | – | +$10.8M |
| Added | EDGEWISE THERAPEUTICS INC | +254,208 | +78.7% | +$10.3M |
35 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | KALVISTA PHARMACEUTICALS INC | -1,835,506 | -100.0% | $-36.9M |
| Reduced | STRYKER CORPORATION | -86,798 | -56.1% | $-27.3M |
| Sold out | QIAGEN NV | -500,000 | -100.0% | $-20.0M |
| Sold out | ABBVIE INC | -75,000 | -100.0% | $-16.3M |
| Reduced | LIVANOVA PLC | -193,436 | -47.9% | $-15.9M |
| Sold out | ILLUMINA INC | -110,370 | -100.0% | $-13.6M |
| Sold out | EDWARDS LIFESCIENCES CORP | -167,155 | -100.0% | $-13.4M |
| Sold out | NEUROCRINE BIOSCIENCES INC | -99,069 | -100.0% | $-13.1M |
| Sold out | KINIKSA PHARMACEUTICALS INTL | -259,184 | -100.0% | $-12.5M |
| Reduced | BOSTON SCIENTIFIC CORP | -268,287 | -59.8% | $-11.5M |
51 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | MBX BIOSCIENCES INCCOM | 800,173 | $44.2M | 4.52% |
| 2 | LLYELI LILLY & CO | 35,000 | $42.0M | 4.30% |
| 3 | CVSCVS HEALTH CORP | 391,791 | $40.5M | 4.15% |
| 4 | DEXCOM INCCOM | 534,767 | $36.0M | 3.69% |
| 5 | PTC THERAPEUTICS INCCOM | 435,691 | $35.5M | 3.64% |
| 6 | ARCUS BIOSCIENCES INCCOM | 919,266 | $28.3M | 2.90% |
| 7 | STRUCTURE THERAPEUTICS INCSPONSORED ADS | 485,661 | $26.1M | 2.67% |
| 8 | VIRIDIAN THERAPEUTICS INCCOM | 1,377,576 | $25.3M | 2.59% |
| 9 | AGIOS PHARMACEUTICALS INCCOM | 669,046 | $24.8M | 2.54% |
| 10 | INHIBRX BIOSCIENCES INCCOM | 256,950 | $24.3M | 2.49% |
67 more rows. Subscribe for $29/month to see every row, download the data and use the API.